within Pharmacolibrary.Drugs.ATC.L;

model L02BG02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 16.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,
    adminCount     = 1,
    Vd             = 0.073,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Formestane is a steroidal aromatase inhibitor that was previously used for the treatment of advanced breast cancer in postmenopausal women. It works by inhibiting the synthesis of estrogens from androgens, thus lowering estrogen levels. Formestane is no longer widely used clinically and has been replaced by newer aromatase inhibitors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for postmenopausal women with advanced breast cancer following a single intramuscular injection.</p><h4>References</h4><ol><li><p>Wiseman, LR, &amp; McTavish, D (1993). Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. <i>Drugs</i> 45(1) 66–84. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199345010-00007&quot;>10.2165/00003495-199345010-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7680986/&quot;>https://pubmed.ncbi.nlm.nih.gov/7680986</a></p></li><li><p>Lønning, PE, et al., &amp; Faigle, JW (2001). Pharmacokinetics and metabolism of formestane in breast cancer patients. <i>The Journal of steroid biochemistry and molecular biology</i> 77(1) 39–47. DOI:<a href=&quot;https://doi.org/10.1016/s0960-0760(01)00029-2&quot;>10.1016/s0960-0760(01)00029-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11358673/&quot;>https://pubmed.ncbi.nlm.nih.gov/11358673</a></p></li><li><p>Goss, PE, &amp; Tye, LM (1997). Anastrozole: a new selective nonsteroidal aromatase inhibitor. <i>Oncology (Williston Park, N.Y.)</i> 11(11) 1697–1708. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9394367/&quot;>https://pubmed.ncbi.nlm.nih.gov/9394367</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L02BG02;
